NCT04486352 · Alliance Foundation Trials, LLC.
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
(EndoMAP)
What this study is about
This is a Phase IB/II multi-group of participants study designed to evaluate the effectiveness and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer.
View original scientific description
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Interventions
DRUG
Atezolizumab - 28 Day Cycle
Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
DRUG
Bevacizumab
Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
DRUG
Ipatasertib
Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
DRUG
Talazoparib
Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
DRUG
Trastuzumab emtansine
Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
DRUG
Tiragolumab
Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
DRUG
Atezolizumab - 21 Day Cycle
Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
DRUG
Inavolisib
Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
DRUG
Letrozole
Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
DRUG
Giredestrant
Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
DRUG
Abemaciclib
Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
Primary outcome measures
Investigator-assessed overall response rate (ORR) of each biomarker cohort
Time frame: 48 Months
AFT-50A Protocol: Overall response rate for each biomarker cohort is defined as the proportion of participants achieving a complete (CR) or partial (PR) response on two consecutive occasions at least 4 weeks apart, as determined by the investigator from AFT50A Protocol: Tumor assessments per RECIST v1.1.
The proportion of participants in each biomarker cohort who remain alive and progression-free for at least 6 months
Time frame: 6 Months
AFT-50B Protocol: Progression free survival rate at 6 months is defined as the proportion of participants who have not experienced disease progression or death from any cause at 6 months, as determined by the investigator according to RECIST v1.1
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy. Prior hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit. Chemotherapy given in conjunction with radiotherapy as a radiosensitizer will be counted as a systemic therapeutic regimen.
- Measurable disease per RECIST 1.1
- Availability of a representative tumor specimen that is suitable for determination of biomarker status via central testing (F1CDx) OR If a patient has a prior F1CDx report from 1 September 2019 or later, those NGS results can be used to determine biomarker status as long as the tumor tissue used in the report was obtained within 5 years prior to prescreening and appropriate signed consent is obtained from the patient.
- Life expectancy \> 12 weeks
- Recovery from effects of recent radiotherapy, surgery, or chemotherapy Key
Where
- Duarte, California
- San Francisco, California
- Washington D.C., District of Columbia
- Miami Beach, Florida
- Chicago, Illinois
- Westwood, Kansas
- Scarborough, Maine
- Boston, Massachusetts
- Minneapolis, Minnesota
- St Louis, Missouri
- Omaha, Nebraska
- Englewood, New Jersey
And 9 more locations — see the full list below.
Collaborators
Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 1, 2026 · Source of record for eligibility and locations